Please assess the completion status of the following clinical trial:

Trial Title: 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histological confirmed advanced well differentiated typical and atypical carcinoid tumors of the lung or thymus~* Patients of all treatment lines including naive patients could have been enrolled~* At least one measurable lesion of disease on CT scan or MRI~* Radiological documentation of disease progression within 12 months prior to randomization~* Adequate liver, renal and bone marrow function~* WHO Performance Status 0-2~Exclusion Criteria:~* Poorly differentiated neuroendocrine carcinoma~* Non-neuroendocrine thymoma~* Patients with severe functional disease who required symptomatic treatment with somatostatin analogs~* Prior therapy with mTOR inhibitors~* History of liver disease~* Baseline QTcF\> 470 msec~* Uncontrolled diabetes mellitus despite adequate therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pasireotide LAR (Type: EXPERIMENTAL): Pasireotide long acting release (LAR) 60 mg will be administered as an intra muscular (i.m.) depot injection once every 28 days starting on Day 1
- Everolimus (Type: EXPERIMENTAL): Everolimus 10 mg taken orally (p.o) once daily starting on Day 1
- Pasireotide LAR and Everolimus Combination (Type: EXPERIMENTAL): Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily starting on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).